Keytruda (pembrolizumab) received FDA approval for intravenous injection for the first-line treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal cancer.
Bavencio (avelumab) has received FDA approval for maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy.
Reblozyl (luspatercept) has received approval from the European Commission for the treatment of:
Guardant Health Inc. launched the GuardantINFORM platform, which includes a clinical-genomic liquid biopsy dataset of advanced cancer patients.
Frederic Pla was named chief operating officer of The Parker Institute for Cancer Immunotherapy.
The American Cancer Society has approved funding for 79 research and training grants totaling $36,2 million in the first of two grant cycles for 2020.
Percy Van Crocker Jr. was named Cancer Treatment Centers of America’s Oncology Data, Analytics & Research Business as President and Co-Founder.
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
FDA has approved Sarclisa (isatuximab-irfc), in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.
FDA has granted an investigational CD30-directed autologous chimeric antigen receptor T cell (CD30 CAR-T) therapy Regenerative Medicine Advanced Therapy designation for treatment of patients with relapsed or refractory CD30-positive classical Hodgkin lymphoma.
